|Name||Afirma® Thyroid FNA Analysis|
|Description||The novel Afirma Gene Expression Classifier (GEC), the centerpiece of the Afirma Thyroid FNA Analysis, helps physicians reduce the number of avoidable surgeries by preoperatively identifying benign nodules among those that were originally classified by cytopathology as indeterminate. The GEC measures the expression of 142 genes to determine if the FNA sample is benign or suspicious for cancer — enabling patients with benign results to potentially avoid unnecessary surgery.|
Veracyte introduced its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs.
|Intended to use||The Afirma Malignancy Classifiers comprise tests for MTC and to assess BRAF V600E gene mutation status, and are intended to provide physicians with preoperative information that can enable them to perform a more appropriate procedure the first time, potentially reducing the need for additional surgeries – and the risks and costs that accompany them.|
|Regulatory Status||CLIA cleared|